Skip to main content

Starling Oncology, Inc.

STLN
Exchange
Nasdaq
Industry
Services-Offices & Clinics of Doctors of Medicine
SEC CIK
0001799191

In the last 90 days, Starling Oncology, Inc. insiders filed 3 open-market purchases and 2 sales; 119 institutions reported holding it in 13F filings for Q2 2026, worth $217.6M in total; no superinvestor holds it.

Other share classesDFPHSTLNW

Q2 2023 vs. Q1 2023

How the institutions holding Starling Oncology, Inc. changed between Q1 2023 and Q2 2023.

All holders in Q2 2023All holders in Q1 2023

13F holders of STLN: Q1 2023 compared with Q2 2023
MeasureQ1 2023Q2 2023Change
Holders3938−1
Shares22.0M13.9M−8.04M (−36.6%)
Value$14.9M$7.66M−$7.19M (−48.4%)

New holders (14)

Institutions that held Starling Oncology, Inc. at the end of Q2 2023 but not at the end of Q1 2023.

Institutions new to STLN in Q2 2023
InstitutionSharesValue% of portfolio
Millennium Management LLC202,678$111.5K0.00%
Y-Intercept (Hong Kong) Ltd138,899$76.4K0.01%
Diametric Capital, LP128,392$70.6K0.03%
Qube Research & Technologies Ltd70,518$38.8K0.00%
Old Mission Capital LLC52,740$29.0K0.00%
Prelude Capital Management, LLC41,217$22.7K0.00%
Cubist Systematic Strategies, LLC35,621$19.6K0.00%
Nwam LLC20,000$11.0K0.00%
Brown Advisory Inc18,674$10.3K0.00%
Mariner, LLC16,911$9.30K0.00%
Point72 Asset Management, L.P.14,147$7.78K0.00%
Point72 Middle East FZE3,226$1.77K0.00%
Citigroup Inc498$2740.00%
Toronto Dominion Bank336$00.00%

Sold out (15)

Institutions that held Starling Oncology, Inc. at the end of Q1 2023 and filed for Q2 2023 without it.